The domestic pharmaceutical machinery industry ushered in the growth period and the future development prospects are optimistic

[ Chemical Machinery Equipment Network Market Analysis ] Up to now, the 2020 annual reports and 2021 quarterly reports of listed pharmaceutical machinery companies have basically disclosed that the overall performance of the industry has performed well.
In the context, the development prospects of the domestic pharmaceutical machinery industry have also received high attention .
Recently, Guohai Securities pointed out that the domestic pharmaceutical equipment industry has gradually faded away from its cyclical nature and ushered in long-term growth.
Pharmaceutical machinery-related companies have continued to improve their research and development capabilities, and their profit models have been upgraded and product technologies have been upgraded.
At the same time, driven by innovation, the long-term demand for Biotech and CDMO is broad, the localization rate is expected to continue to increase, and the export business will also develop rapidly with the improvement of corporate strength.
The bank is optimistic about the vigorous development prospects of the domestic pharmaceutical equipment industry.

The medical reform environment has changed, and the demand for high-end pharmaceutical machines has grown
 

From the perspective of the downstream environment of the pharmaceutical machinery industry, in recent years, a series of medical reform policies such as consistency evaluation and drug purchases have been continuously introduced, forcing the domestic pharmaceutical industry to transform and upgrade in the direction of innovation.
In this context, the high-end pharmaceutical industry Equipment demand ushered in growth.

 

Under the new situation, in order to meet the new needs of pharmaceutical companies, domestic pharmaceutical equipment companies continue to increase R&D investment, starting to shift from single machine sales to production line and system package sales, from traditional injections to more complex raw materials, biological macromolecules and other emerging Field upgrades, the overall transformation from low-end to mid-to-high-end, continuously improving product quality and added value.

 

Take the domestic pharmaceutical giants Chutian Technology and Tofflon as examples.
In recent years, Chutian Technology’s R&D expenditure has basically accounted for about 10% of its operating income; Tofflon’s R&D expenses also continue to be high in R&D in 2020.
Investment increased by 31.
16% year-on-year to 156 million yuan, accounting for 5.
77%.
With continuous high R&D investment, Chutian opened up the high-end vaccine equipment market, breaking the previous situation where domestic high-end pharmaceutical equipment was monopolized by foreign companies.
Tofflon is also moving towards the high-end field of freeze-drying systems, accelerating the internationalization of its layout.  

　　Accelerating the pace of domestic substitution, driving performance improvement
 

　　From the perspective of market demand, under the influence of the epidemic, the demand for pharmaceutical machine products including vaccine-related production equipment has increased.
Compared with overseas pharmaceutical machine companies, domestic pharmaceutical machine companies have stronger delivery capabilities and can promptly comply with market demand and accelerate domestic production.
Substitute.
For example, Chutian Technology has continuously increased its investment in scientific research since 2020 to improve the efficiency and production capacity of vaccine-related production equipment.
Among them, the cutting efficiency of the boxing machine of the intelligent after-packing product line has been greatly improved, breaking the original industry bottleneck of 200 boxes per minute, reaching Up to 300 boxes can be cut in one minute, breaking the monopoly of developed countries in related equipment.

 

　　At the same time, while meeting the needs of domestic pharmaceutical companies, some pharmaceutical machinery companies are also accelerating their internationalization, promoting the development of products in overseas markets, increasing their international market share, and driving performance improvements in the future.
For example, in recent years, Chutian has participated in international market competition by accelerating the pace of overseas expansion.
At present, the company has realized the integration of international ideas, talents and technology, and the process of internationalization has been further accelerated.
According to the company's plan, by 2025, Chutian Technology's global sales are expected to reach 20 billion yuan, and its overseas business will be no less than 10 billion yuan, occupying "half of the country.
" Tofflon has successfully entered the high-regulation markets in Western Europe and North America.
The company has also gradually established design offices and technology centers in Europe and India, established joint ventures and carried out technical cooperation with European and Japanese partners, and has five competitive modern pharmaceutical equipment production bases.  

　　The rapid development of emerging industries brings growth points to the pharmaceutical industry
 

　　The emerging Biotech and CDMO industries are ushering in a period of development.
In terms of the number of Biotech, the number of Biotech companies in China in 2020 (including listed and unlisted) will reach 865, accounting for 14% of the global total.
The industry predicts that the proportion of China's Biotech companies will increase to 25%-30% in the next five years.

 

　　In the context of the vigorous development of the innovative medicine industry, the demand for local medical innovation outsourcing services is expanding rapidly, and the CDMO industry has a large room for development.
According to statistics from the IFC Big Data Center, from 2016 to 2020, the revenue of the small molecule CDMO sector of listed companies increased from 22% year-on-year to 39% year-on-year, and the growth rate has increased significantly for three consecutive years.

 

　　The analysis believes that these emerging industries will have strong demand for capacity expansion in the future, which will inject new growth momentum into the development of pharmaceutical equipment.

 

　　Original title: The domestic pharmaceutical machinery industry ushered in the growth period and the future development prospects are optimistic